title: The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.
abstract: The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many patients with chronic myeloid leukemia (CML), but some cases are resistant to this treatment. To compare the prognostic performance of Sokal, Hasford, and European Treatment and Outcome Study (EUTOS) scores, patient outcomes and treatment responses were investigated following the European LeukemiaNet (ELN) 2013 recommendations. Seventy-three patients with newly diagnosed chronic-phase CML (CML-CP) treated with any tyrosine kinase inhibitor as initial therapy were analyzed. All scoring systems significantly predicted treatment response at 3 and 6 months; however, only the EUTOS score significantly predicted treatment response at 12 months, following the ELN 2013 recommendations. The 5-year event-free survival rates were 93 and 35 % in the low- and high-risk groups according to the EUTOS score (P < 0.0001). Moreover, the 5-year overall survival rates were 98 and 51 % in the low- and high-risk groups by EUTOS score (P < 0.0001). We suggest that the EUTOS score may provide a better stratification of CML-CP patients for predicting treatment response.
authors.affiliation: Department of Hematology and Rheumatology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan, iriyama.noriyoshi@nihon-u.ac.jp.
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Iriyama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hatta
authors.forename: Sumiko
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Uchino
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Miura
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kurita
authors.forename: Hitomi
authors.initials: H
authors.lastname: Kodaira
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Inoue
authors.forename: Masami
authors.initials: M
authors.lastname: Takei
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D047428:Protein Kinase Inhibitors
references.citation: Blood. 2012 May 10;119(19):4524-6
references.pmid: 22431574
references.citation: Int J Hematol. 2012 Mar;95(3):263-73
references.pmid: 22351162
references.citation: Leukemia. 2002 Mar;16(3):393-9
references.pmid: 11896544
references.citation: J Clin Oncol. 2011 Aug 10;29(23):3173-8
references.pmid: 21747082
references.citation: Blood. 2013 Aug 8;122(6):872-84
references.pmid: 23803709
references.citation: Leukemia. 2013 Oct;27(10):2016-22
references.pmid: 23752173
references.citation: N Engl J Med. 2003 Mar 13;348(11):994-1004
references.pmid: 12637609
references.citation: N Engl J Med. 2010 Jun 17;362(24):2251-9
references.pmid: 20525993
references.citation: Int J Hematol. 2012 May;95(5):535-44
references.pmid: 22461032
references.citation: Leuk Res. 2013 Nov;37(11):1457-60
references.pmid: 23993428
references.citation: Int J Hematol. 2012 Jul;96(1):47-57
references.pmid: 22610512
references.citation: Cancer Sci. 2012 Jun;103(6):1071-8
references.pmid: 22364419
references.citation: J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
references.pmid: 9625174
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: Ann Hematol. 2014 Jan;93(1):163-4
references.pmid: 24292539
references.citation: Leuk Res. 2011 May;35(5):585-90
references.pmid: 21145591
references.citation: Cancer Sci. 2014 Jan;105(1):105-9
references.pmid: 24450386
references.citation: Blood. 2011 Jul 21;118(3):686-92
references.pmid: 21536864
references.citation: Blood. 1984 Apr;63(4):789-99
references.pmid: 6584184
references.citation: N Engl J Med. 2010 Jun 17;362(24):2260-70
references.pmid: 20525995